about
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis.Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.Omalizumab in asthma: an update on recent developments.Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy.Tenidap: not just another NSAID?Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled StudyHealthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world settingOmalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developmentsA 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO studyInfrared spectroscopy: shedding light on synovitis in patients with rheumatoid arthritisSynovial distribution of αd/CD18, a novel leukointegrin. Comparison with other integrins and their ligandsSignificance of cytokine measurements in patients with juvenile rheumatoid arthritis: comment on the article by mangge et alMinocycline in Rheumatoid ArthritisClomiphene therapy and its potential role in rheumatic symptoms: comment on the article by a. and e. ben-chetritPossible precursor of diaphragm disease in the small intestineCyclosporine for the treatment of granulocytopenia in Felty's syndrome
P50
Q34035726-B05B169F-3709-4636-B731-5053E0868195Q34358122-E460A074-1CFD-4460-A552-42628A505B68Q34627039-AF49AB91-1BAC-48C8-811C-5534F0CAAE7CQ34727734-38F201B2-0B40-4F7F-8474-BDF143B8D922Q38248469-CEAF5446-30B4-42D9-9D56-80927EAF713BQ38606180-99410531-6CF4-4F3C-8904-CBD4940CD82BQ41036582-8CF89081-C284-443E-A0E3-A73EF45F5BC1Q41701492-517FDACC-8C11-4A03-AFC0-A141024B2A9CQ57919514-C945FBEF-93E3-45B2-944C-DF8E6531D3FCQ58900297-99D873A5-9181-4F2D-956D-70E0CD4EC311Q58900301-4C002A97-A668-4117-8602-B4F1FBA7BACBQ58900306-3343DDD5-97B1-44F8-B3EA-140077AE67BAQ58900312-4D1A0C72-D5FB-415A-910E-2332FBF8746AQ58900318-855497CF-3836-4AC5-87AB-C024992B1B84Q58900322-7482207A-7505-4A04-AA94-2D910155893DQ58900326-4EB9C40A-3A7A-4006-98A1-9E70B557B899Q58900330-397D9A1B-5F2F-4DFA-B783-8B2DA2528FF6Q58900334-9424032A-2F7B-464F-922F-0B24DB8084FCQ58900338-F1319207-FB95-46E1-9773-6ED75BBA728B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Janice Canvin
@ast
Janice Canvin
@en
Janice Canvin
@es
Janice Canvin
@nl
type
label
Janice Canvin
@ast
Janice Canvin
@en
Janice Canvin
@es
Janice Canvin
@nl
prefLabel
Janice Canvin
@ast
Janice Canvin
@en
Janice Canvin
@es
Janice Canvin
@nl
P106
P31
P496
0000-0001-9609-7182